Drugs / OPM-101
last change Sep 2025 re-read 2 minutes ago

OPM-101

Developed for
melanoma
Investigated by
Oncodesign Precision Medicine

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07040436 Sep 2025 → Sep 2027 expected melanoma Oncodesign Precision Medicine Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as OPM-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07040436
Route Oral “daily oral treatment with OPM-101” NCT07040436